AzTrials
AzTrials

Critically IllNCT02815527

Time to Protein Target Using a High Whey Protein Enteral Nutrition in Critically Ill Patients

An observational study of Critically Ill, run by Amsterdam UMC, location VUmc at 1 site in Netherlands.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study evaluates the feasibility of a high whey-protein enteral nutrition formula in 20 ventilated ICU patients. The primary endpoint of study is the feasibility to attain the individualized protein target (≥1.2 g/kg ideal body weight/day) 96-hours after ICU admission. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Critically Ill
What is being tested?
Fresubin intensive
How many people
20 participants
Where
1 siteNetherlands
Study dates
Mar 2016to Sep 2017
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Ventilated critically ill patients in the ICU

Who may be able to join

  • Admission to the intensive care unit
  • Age >18 years
  • Mechanical ventilation
  • Expected intensive care stay of four days or longer

Who cannot join

  • Contraindication for enteral nutrition (gut ischemia, obstruction or perforation)
  • Expected intolerance for enteral nutrition (paralytic ileus)
  • Inability to start enteral nutrition within 24-hours due to logistic reasons (i.e. surgery or other interventions)
  • Short bowel syndrome
  • Child C liver cirrhosis or acute liver failure
  • Dialysis dependency
Show all 11Show fewer
  • Requiring other specific enteral nutrition for medical reason
  • Extensive treatment limitations
  • Written deferred patient or proxy consent is not obtained
  • Participation in another intervention study
  • Inability to measure energy expenditure (pulmonary air leakage)

Trial locations and contacts

1 site in 1 country.

Netherlands1 site
  • VU Medical Center

    Amsterdam, North Holland

Other trials in Netherlands

About this study

Official title: Time to Protein Target, the 'HIGH WHEY' Study A Prospective Pilot Study

This study evaluates the feasibility of a high whey-protein enteral nutrition formula in 20 ventilated ICU patients. The primary endpoint of study is the feasibility to attain the individualized protein target (≥1.2 g/kg ideal body weight/day) 96-hours after ICU admission. Secondary endpoints include tolerance and efficacy in terms of the amino acid response in blood.

Read the detailed description

In the present pilot study, the investigators will use a high whey-protein nutrition formula during the first four days of ICU admission. The reason for using a high protein nutrition is that the investigators previously found that an early high protein intake in non-septic non-overfed patients was associated with lower hospital mortality (Weijs PJM et. al., Critical Care 2014,18). Furthermore, during the first days of critical illness tolerance to full enteral nutrition is often diminished. The use of a high protein nutrition will facilitate an early high protein intake.

The whey protein is hydrolysed. Hydrolyzation of protein prevents coagulation and subsequent solidification in the digestive tract and therefore promotes efficient absorption of the protein. Of all nutrition proteins, whey protein has the largest leucin content. Leucin is crucial for muscle protein synthesis. (Meyer RF, et.al.: BMC Gastroenterol 2015, 15), (Marik PE: Ann Intensive Care 2015,5:51)

Our previous observational data also showed that early overfeeding was associated with higher mortality, while an intake of 80-100% of measured energy expenditure at day 4 of ICU admission was associated with lower mortality. (Weijs PJM et. al., Critical Care 2014, 18)

Therefore, the energy target during the first four days will be 90% of the measured Energy Expenditure (EE). To optimize energy intake, the investigators will measure EE by metabolic monitoring (Deltatrac®, Datex, Helsinki, Finland), If metabolic monitoring is not available, the investigators will assess EE from the ventilator derived VCO2 (8.19*VCO2). (Stapel S, et.al., Critical Care 2015,19:370)

Conditions
Critically Ill
Being tested
Fresubin intensive
Keywords
enteral nutrition, intensive care unit, whey, protein, muscle mass, leucin, energy expenditure
Medical subject headings
Critical Illness

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Fresubin intensiveOther

    Enteral nutrition containing a high protein concentration

Study groups in NCT02815527
Study groupRoleWhat they receive
Fresubin IntensiveAdult critically ill non-septic ventilated patients admitted to the intensive care unit with an expected intensive care stay of four days or more.
Receives: Other: Fresubin intensive

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The proportion of patients reaching the individualized protein target (≥1.2 g/kg ideal body weight/day) 96 hours after ICU admission

    Protein target

    Measured: 96 hours

Secondary outcomes (7)
  1. Protein intake 48 hours and 96 hours after start (g/day)

    Protein intake

    Measured: 48 and 96 hours

  2. Number of patients with adverse events related to nutrition, as defined by: high gastric retention,abdominal distension, vomiting, diarrhea, need of prokinetics or duodenal tube

    Gastro-intestinal tolerance

    Measured: During 96 hours

  3. Plama leucine concentration (μmol/L)

    Amino acid plasma concentration

    Measured: 0, 48, and 96 hours

  4. Muscle mass (kg)

    Measured using bioimpedance analysis

    Measured: 48 and 96 hours

  5. Plasma urea concentration (mmol/l)

    Metabolic tolerance

    Measured: 48 and 96 hours

  6. Cumulative protein intake 96 hours after start of the study formula (grams)

    Cumulative protein intake

    Measured: 96 hours

  7. Time to protein target (protein intake ≥ 1.2 g/kg/day).

    Time to target

    Measured: Up to 96 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Jun 2016 (estimated)
  2. Study startMar 2016
  3. Primary completionJun 2017
  4. Study completionSep 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02815527
Sponsor's protocol ID
2015.560
Status last verified
Nov 2017
First submitted
9 May 2016
Last updated
7 Nov 2017
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Publications

  • Meyer R, Foong RX, Thapar N, Kritas S, Shah N. Systematic review of the impact of feed protein type and degree of hydrolysis on gastric emptying in children. BMC Gastroenterol. 2015 Oct 15;15:137. doi: 10.1186/s12876-015-0369-0.

    PubMed 26472544
  • Marik PE. Feeding critically ill patients the right 'whey': thinking outside of the box. A personal view. Ann Intensive Care. 2015 Dec;5(1):51. doi: 10.1186/s13613-015-0051-2. Epub 2015 May 28.

    PubMed 26055186
  • Weijs PJ, Looijaard WG, Beishuizen A, Girbes AR, Oudemans-van Straaten HM. Early high protein intake is associated with low mortality and energy overfeeding with high mortality in non-septic mechanically ventilated critically ill patients. Crit Care. 2014 Dec 14;18(6):701. doi: 10.1186/s13054-014-0701-z.

    PubMed 25499096
  • Stapel SN, de Grooth HJ, Alimohamad H, Elbers PW, Girbes AR, Weijs PJ, Oudemans-van Straaten HM. Ventilator-derived carbon dioxide production to assess energy expenditure in critically ill patients: proof of concept. Crit Care. 2015 Oct 22;19:370. doi: 10.1186/s13054-015-1087-2.

    PubMed 26494245

Questions about this trial

What is this clinical trial studying?

An observational study of Critically Ill, run by Amsterdam UMC, location VUmc at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Nov 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The proportion of patients reaching the individualized protein target (≥1.2 g/kg ideal body weight/day) 96 hours after ICU admission (time frame: 96 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02815527, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Nov 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in